Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours Β· Estimated delivery Aug 9 - Aug 14
Gastrointestinal Adverse Reactions In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients who received RYBELSUS than placebo: RYBELSUS 14 mg once daily (41%), RYBELSUS 7 mg once daily (32%) and placebo (21%), including severe reactions (RYBELSUS 14 mg 2.0%, RYBELSUS 7 mg 0.6%, placebo 0.3%)
That means GLP-1 receptor agonist users were more than twice as likely to develop allodynia compared to an active comparator group, not just compared to the general population
In SUSTAIN-6, in adults with type 2 diabetes at high cardiovascular risk, semaglutide reduced the same composite to 6.6% versus 8.9% (hazard ratio 0.74, about a 26% relative reduction)
Earlier this week, the company Hims, arguably the best-known source of compounded GLP-1s, announced that it would stop marketing these drugs as part of a truce formed with Novo Nordisk
Drivers 11.2
They represent real patients who might discontinue treatment without proper support
US$ 26.62
US$ 27.45
US$ 20.47
